CD20-targeting in B-cell malignancies: novel prospects for antibodies and combination therapies.
about
Prognostic stratification improvement by integrating ID1/ID3/IGJ gene expression signature and immunophenotypic profile in adult patients with B-ALL.Pharmacokinetics, efficacy and safety of the rituximab biosimilar CT-P10.Therapeutic antibody targeting of indoleamine-2,3-dioxygenase (IDO2) inhibits autoimmune arthritis.
P2860
CD20-targeting in B-cell malignancies: novel prospects for antibodies and combination therapies.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
CD20-targeting in B-cell malig ...... ies and combination therapies.
@en
type
label
CD20-targeting in B-cell malig ...... ies and combination therapies.
@en
prefLabel
CD20-targeting in B-cell malig ...... ies and combination therapies.
@en
P2860
P1476
CD20-targeting in B-cell malig ...... ies and combination therapies.
@en
P2093
Vahideh Ahmadzadeh
P2860
P2888
P304
P356
10.1007/S10637-016-0349-4
P577
2016-04-13T00:00:00Z
P6179
1040928004